Published in NMR Biomed on November 01, 1998
Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res (2010) 1.81
Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer (2001) 1.73
Molecular imaging for personalized cancer care. Mol Oncol (2012) 1.28
Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med (2008) 1.25
Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol (2011) 1.16
Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy. Br J Cancer (2009) 1.16
Imaging in breast cancer: Magnetic resonance spectroscopy. Breast Cancer Res (2005) 1.11
Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway. NMR Biomed (2009) 1.10
Molecular Imaging of Cancer: Applications of Magnetic Resonance Methods. Proc IEEE Inst Electr Electron Eng (2005) 1.02
Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer. Top Magn Reson Imaging (2008) 0.99
Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition. Oncotarget (2010) 0.98
Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia (2006) 0.97
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. Neoplasia (2008) 0.97
Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MRS. NMR Biomed (2010) 0.92
HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells. PLoS One (2013) 0.91
Imaging biochemistry: applications to breast cancer. Breast Cancer Res (2000) 0.88
Human in-vivo 31P MR spectroscopy of benign and malignant breast tumors. Korean J Radiol (2001) 0.87
Breast imaging in the new era. Cancer Imaging (2004) 0.86
The C-neu mammary carcinoma in Oncomice; characterization and monitoring response to treatment with herceptin by magnetic resonance methods. MAGMA (2004) 0.85
Detection of alterations in membrane metabolism during neoadjuvant chemotherapy in patients with breast cancer using phosphorus magnetic resonance spectroscopy at 7 Tesla. Springerplus (2014) 0.82
Breast Tissue Metabolism by Magnetic Resonance Spectroscopy. Metabolites (2017) 0.79
Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy. BMC Res Notes (2012) 0.79
Metformin Decouples Phospholipid Metabolism in Breast Cancer Cells. PLoS One (2016) 0.77
Targeting Phospholipid Metabolism in Cancer. Front Oncol (2016) 0.77
Magnetic resonance in the detection of breast cancers of different histological types. Magn Reson Insights (2013) 0.76
1H/31P polarization transfer at 9.4 Tesla for improved specificity of detecting phosphomonoesters and phosphodiesters in breast tumor models. PLoS One (2014) 0.76
Probing the PI3K/Akt/mTor pathway using (31)P-NMR spectroscopy: routes to glycogen synthase kinase 3. Sci Rep (2016) 0.75
Proton and phosphorus magnetic resonance spectroscopy of the healthy human breast at 7 T. NMR Biomed (2016) 0.75
Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas. Nature (1982) 9.12
Analysis of avian leukosis virus DNA and RNA in bursal tumours: viral gene expression is not required for maintenance of the tumor state. Cell (1981) 6.98
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet (1997) 5.59
Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet (1994) 4.03
Gene dosage-dependent secretion of yeast vacuolar carboxypeptidase Y. J Cell Biol (1986) 3.85
The AP-3 adaptor complex is essential for cargo-selective transport to the yeast vacuole. Cell (1997) 3.30
A role for clathrin in the sorting of vacuolar proteins in the Golgi complex of yeast. EMBO J (1992) 3.10
An outbreak of waterborne cryptosporidiosis caused by post-treatment contamination. Epidemiol Infect (1989) 3.06
A cost benefit study of milk-borne salmonellosis. J Hyg (Lond) (1983) 2.99
Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet (1980) 2.82
In vitro and in vivo radiosensitivity of human tumour cells obtained from a pancreatic carcinoma xenograft. Nature (1976) 2.77
Cost-sharing strategies combining targeted public subsidies with private-sector delivery achieve high bednet coverage and reduced malaria transmission in Kilombero Valley, southern Tanzania. BMC Infect Dis (2007) 2.75
Selective and immediate effects of clathrin heavy chain mutations on Golgi membrane protein retention in Saccharomyces cerevisiae. J Cell Biol (1992) 2.60
Heterogeneity of genetic loci in chickens: analysis of endogenous viral and nonviral genes by cleavage of DNA with restriction endonucleases. Cell (1979) 2.55
Rugby injuries. BMJ (1991) 2.54
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol (1982) 2.50
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol (1993) 2.50
Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol (2008) 2.46
Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol (2006) 2.40
A test of clathrin function in protein secretion and cell growth. Science (1985) 2.36
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Costing of a hospital-based outbreak of poultry-borne salmonellosis. Epidemiol Infect (1988) 2.28
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Vps1p, a member of the dynamin GTPase family, is necessary for Golgi membrane protein retention in Saccharomyces cerevisiae. EMBO J (1993) 2.26
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol (1998) 2.18
Clathrin facilitates the internalization of seven transmembrane segment receptors for mating pheromones in yeast. J Cell Biol (1993) 2.14
A comparison of children affected by prenatal alcohol exposure and attention deficit, hyperactivity disorder. Alcohol Clin Exp Res (1997) 2.13
A colony-forming assay for human tumour xenografts using agar in diffusion chambers. Br J Cancer (1976) 2.11
Adaptor complex-independent clathrin function in yeast. Mol Biol Cell (1999) 2.10
Detection of micrometastases in patients with primary breast cancer. Lancet (1983) 2.07
The occurrence, metabolism and functions of amines in plants. Biol Rev Camb Philos Soc (1971) 2.06
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res (1995) 2.05
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res (1987) 2.03
Production of plant growth inhibitors from xanthophylls: a possible source of dormin. Nature (1967) 1.92
Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet (1976) 1.92
The association between typhoid carriage, typhoid infection and subsequent cancer at a number of sites. Eur J Cancer Prev (1995) 1.89
Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet (1980) 1.88
Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer (2004) 1.87
The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer (1973) 1.81
Survey of treatment of primary breast cancer in Great Britain. Br Med J (Clin Res Ed) (1985) 1.80
Clathrin-dependent localization of alpha 1,3 mannosyltransferase to the Golgi complex of Saccharomyces cerevisiae. J Cell Biol (1994) 1.79
Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol (2008) 1.76
The di- and poly-amine oxidases of higher plants. Biochem Soc Trans (1985) 1.75
ABC of sports medicine. Infections in sport. BMJ (1994) 1.75
Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer (1983) 1.73
Yeast Gga coat proteins function with clathrin in Golgi to endosome transport. Mol Biol Cell (2001) 1.72
The role of low level Plasmodium falciparum parasitaemia in anaemia among infants living in an area of intense and perennial transmission. Trop Med Int Health (1997) 1.72
Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia (2000) 1.72
Grey scale echography in the diagnosis of intrahepatic disease. J Clin Ultrasound (1973) 1.71
Ultrasound and scintigraphy in the differential diagnosis of obstructive jaundice. J Clin Ultrasound (1974) 1.70
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer (2004) 1.69
Respiratory and allergic symptoms in wool textile workers. Br J Ind Med (1988) 1.67
Palliative chemotherapy for advanced non-small cell lung cancer. BMJ (1994) 1.67
Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol (1991) 1.66
Tamoxifen for the prevention of breast cancer. Eur J Cancer (2000) 1.62
Applications of sliding window reconstruction with cartesian sampling for dynamic contrast enhanced MRI. NMR Biomed (2002) 1.61
Pasteurisation and the control of milkborne infection in Britain. Br Med J (Clin Res Ed) (1985) 1.60
Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol (2005) 1.59
FDG accumulation and tumor biology. Nucl Med Biol (1998) 1.59
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol (2005) 1.58
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer (1997) 1.52
Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy. Ann Oncol (1999) 1.51
Measurement reproducibility of perfusion fraction and pseudodiffusion coefficient derived by intravoxel incoherent motion diffusion-weighted MR imaging in normal liver and metastases. Eur Radiol (2012) 1.51
Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. Eur J Cancer Clin Oncol (1987) 1.51
Breast cancer in adolescents and young women. Eur J Cancer (2003) 1.49
Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet (1994) 1.49
The potential of intratumoural unsealed radioactive source therapy. Eur J Nucl Med (2001) 1.49
Biochemical markers in human breast cancer. Lancet (1977) 1.48
Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer (2005) 1.48
Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer. Lancet (1995) 1.47
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol (1987) 1.47
c-erbB-2 expression in benign and malignant breast disease. Br J Cancer (1988) 1.47
Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet (1987) 1.46
Growth of human tumour cell colonies from biopsies using two soft-agar techniques. Br J Cancer (1978) 1.46
Future directions for unsealed source radionuclide therapy for bone metastases. Eur J Nucl Med Mol Imaging (2002) 1.45
Poultry-borne salmonellosis in Scotland. Epidemiol Infect (1988) 1.45
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer (2000) 1.45
Human and animal salmonellosis in Scotland associated with environmental contamination, 1973-79. Vet Rec (1981) 1.44
Retroperitoneal leiomyosarcomas unassociated with the gastrointestinal tract: a clinicopathologic analysis of 17 cases. Mod Pathol (1999) 1.44
A dileucine-like sorting signal directs transport into an AP-3-dependent, clathrin-independent pathway to the yeast vacuole. EMBO J (1998) 1.44
Clinical examination, xeromammography, and fine-needle aspiration cytology in diagnosis of breast tumours. Br Med J (1978) 1.44
Phage type/biotype groups of Salmonella typhimurium in Scotland 1974-6: variation during spread of epidemic clones. J Hyg (Lond) (1980) 1.44
Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol (2007) 1.43
Viability of clathrin heavy-chain-deficient Saccharomyces cerevisiae is compromised by mutations at numerous loci: implications for the suppression hypothesis. Mol Cell Biol (1991) 1.42
Physical test for distant metastases in patients with breast cancer. J R Soc Med (1980) 1.42
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab (1993) 1.41
New treatments for advanced cancer: an approach to prioritization. Br J Cancer (2000) 1.41
The metabolic fate of 4-chloro-2-methyl-phenoxyacetic acid in peas. Biochem J (1970) 1.40
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol (2009) 1.40
Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat (1998) 1.39
Prevention of breast cancer. Curr Opin Oncol (1991) 1.39
Escherichia coli O157 infections: the Scottish experience. Hosp Med (1998) 1.39